Attention Deficit/Hyperactivity Disorder (ADHD) is the most common psychiatric disorder in children. Pycnogenol®, an extract from the bark of the French maritime pine, consisting of phenolic acids, catechin, taxifolin and procyanidins, has shown improvement of ADHD in case reports and in an open study. Aim of the present study was to evaluate the effect of Pycnogenol® on ADHD symptoms. Sixty-one children were supplemented with 1 mg/kg/day Pycnogenol® or placebo over a period of 4 weeks in a randomised, placebo-controlled, doubleblind study. Patients were examined at start of trial, 1 month after treatment and 1 month after end of treatment period by standard questionnaires: CAP (Child Attention Problems) teacher rating scale, Conner’s Teacher Rating Scale (CTRS), the Conner’s Parent Rating Scale (CPRS) and a modified Wechsler Intelligence Scale for children. Results show that 1-month Pycnogenol® administration caused a significant reduction of hyperactivity, improves attention and visual–motoric coordination and concentration of children with ADHD. In the placebo group no positive effects were found. One month after termination of Pycnogenol® administration a relapse of symptoms was noted. Our results point to an option to use Pycnogenol as a natural supplement to relieve ADHD symptoms of children.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
body mass index
Child Attention Problems
The Conner’s Parent Rating Scale
The Conner’s Teacher rating Scale
International Statistical Classification of Diseases and Related Health Problems
Prague Wechsler Intelligence Scale for children
Wechsler Intelligence Scale for children
Barkley RA (1990) Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment. Guilford Press, New York
Biederman J (2005) Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 57:1215–1220
Buitelaar JK, Danckaerts M, Gillberg C, Zuddas A, Becker K, Bouvard M, Fagan J, Gadoros J, Harpin V, Hazell P, Johnson M, Lerman-Sagie T, Soutullo CA, Wolanczyk T, Zeiner P, Fouche DS, Krikke-Workel J, Zhang S, Michelson D (2004) A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescent with ADHD. Eur Child Adolesc Psychiatry 13:249–257
Conners CK, Sitarenios G, Oarker JDA, Epstein JN (1998) The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and Criterion Validity. J Abnorm Child Psychol 26:257–268
Dulcan MK, Popper CW (1991) Concise guide to child and adolescent psychiatry. American Psychiatric Press, Washington
Ďuračková Z, Muchová J, Sivoňová M, Chovanová Z, Hauserová M, Blažíček P, Trebatická J, Rohdewal P (2004) Oxidative stress in pathophysiology of attention deficit hyperactivity disorder and its influence by a polyphenolic natural extracts, pycnogenol. In: Hoikkala A, Soidinsal O, Wähälä K (eds) XXII International Conference on Polyphenols “Polyphenols communications 2004” Helsinki, Finland, 25–28 August 2004. Jyväskyla, Gummerus Printing, pp 177–178, ISBN 952-10-1977-8
Fitzpatrick DF, Bin B, Rohdewald P (1998) Endothelium-dependent vascular effects of Pycnogenol. J Cardiovasc Pharmacol 32:509–515
Gillberg C, Gillberg IC, Rasmussen P, Kadesjo B, Soderstrom H, Rasatam M, Johnson M, Rothenberger A, Niklasson L (2004) Co-existing disorders in ADHD – implications for diagnosis and intervention. Eur Child Adolesc Psychiatry 13:180–192
Grosse Düweler K, Rohdewald P (2000) Urinary metabolites of French maritime pine bark extract in humans. Pharmazie 55:364–368
Hanley JL (1999) Attention deficit disorder. Impact Communications Inc, Green Bay
Heimann SW (1999) Pycnogenol® for ADHD? J Am Acad Child Adolesc Psychiatry 38:357–358
Ingram DK, Shimada A, Spangler EL, Ikari H, Hengemihle J, Kuo H, Greig N (1996) Cognitive enhancement. New strategies for stimulating cholinergic, glutamatergic, and nitric oxide systems. Ann NY Acad Sci 786:348–361
Kaminester DD (1997) Attention Deficit Hyperactivity Disorder and methylphenidate: when society misunderstands medicine. McGill J Med 3:105–114
Kubička L, Bursik R, Jirásek J (1973) PDW – Prague child Wechsler. Psychodiagnostic and didactic tests, Bratislava (in Slovak)
Liu F, Zhang Y, Lau BHS (1999) Pycnogenol® improves learning impairment and memory deficit in senescence-accelerated mice. J Anti Aging Med 2:349–355
Malá E (2000) Hyperkinetické poruchy (F90) In: Hort V, Hrdlička M, Kocourková J, Malá E (eds) Dětská a adolescentní psychiatrie. Portál, Praha pp 307–314
Masao H (2000) Pycnogenol®’s therapeutic effect in improving ADHD symptoms in children. Mainichi Shimbun, Oct. 21
Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:E83
Packer L, Rimbach G, Virgili F (1999) Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, Pycnogenol. Free Rad Biol Med 27:704–724
Paclt I, Florian J (1998) Dotazník pro rodiče (CPQ-Conners instrukce). In: Paclt I, Florian J Psychofarmakoterapie dětského a dorostového věku. Praha, Grada Publishing, pp 296–303 (in Slovak)
Passwater RA (1998) All about Pycnogenol®. Avery Publishing Group, New York
Pogun S, Kuhar MJ (1994) Regulation of neurotransmitter reuptake by nitric oxide. Ann NY Acad Sci 738:305–315
Rohdewald PJ (2005) Pycnogenol®, French maritime pine bark extract In: Coates PM, Blackman MR, Cragg G, Levine M, Moss J, White J (eds) Encyclopedia of dietary supplements. Marcel Dekker, New York, pp 545–553, ISBN 0-8247-5504-9
Schmidt HW, Walter U (1994) NO at work. Cell 78:919–925
Stanislavov R, Nikolova V (2005) Prelox® Plus testosterone for achieving fertilization in previously infertile men. Eur Bull Drug Res 13: 7–13
Stough C, Ryan J, Croft K (2004) Anti-oxidants to ameliorate normal cognitive deterioration due to age. Presented at the International Conference On Healthy Ageing and Longevity. Sydney, Australia, March 5–7, 2004
Tenenbaum S, Paull JC, Sparrow EC, Dodd DK, Green L (2002) An experimental comparison of Pycnogenol® and methylphenidate in adults with Attention-Deficit/Hyperactivity Disorder (ADHD). J Atten Disord 6:49–60
Trebatická J, Škodáček I, Šuba J, Kopasová S, Hradečná Z, Činovský K, Rohdewald P, Ďuračková Z (2004) Treatment success of ADHD by Pycnogenol®. In: Hoikkala A, Soidinsal O, Wähälä K (eds) XXII International Conference on Polyphenols “Polyphenols communications 2004” Helsinki, Finland, 25–28 August 2004. Jyväskyla, Gummerus Printing, pp 179–180, ISBN 952-10-1977-8
Yamada K, Noda Y, Nakayama S, Komori Y, Sugihara H, Hasegawa T, Nabeshima T (1995) Role of nitric oxide in learning and memory and in monoamine metabolism in the rat brain. Br J Pharmacol 115:852–858
This study was supported by Horphag Res. Ltd. grant, partly by VEGA Grants No. 1/1157/04, 1/3037/06, Grant VV MVTS 03/LF of Ministry of Education of SR, by Drug Research Institute, Modra, SR and Mind&Health, civil association. Authors wish to thank to Assoc. Prof. P. Blažíček, PhD for the biochemical analyses, to Mrs. Ľ’. Chandogová and L. Míková for their technical assistance.
About this article
Cite this article
Trebatická, J., Kopasová, S., Hradečná, Z. et al. Treatment of ADHD with French maritime pine bark extract, Pycnogenol® . Eur Child Adolesc Psychiatry 15, 329–335 (2006). https://doi.org/10.1007/s00787-006-0538-3